Van Berkom & Associates Inc. Grows Stock Holdings in Privia Health Group, Inc. $PRVA

Van Berkom & Associates Inc. increased its holdings in Privia Health Group, Inc. (NASDAQ:PRVA) by 30.1% during the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 3,774,565 shares of the company’s stock after buying an additional 873,344 shares during the period. Privia Health Group accounts for approximately 2.7% of Van Berkom & Associates Inc.’s portfolio, making the stock its 8th largest holding. Van Berkom & Associates Inc.’s holdings in Privia Health Group were worth $93,987,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the business. CWM LLC increased its stake in Privia Health Group by 89.4% in the 2nd quarter. CWM LLC now owns 3,416 shares of the company’s stock worth $79,000 after acquiring an additional 1,612 shares during the last quarter. Canada Pension Plan Investment Board grew its holdings in shares of Privia Health Group by 48.0% during the second quarter. Canada Pension Plan Investment Board now owns 3,700 shares of the company’s stock worth $85,000 after purchasing an additional 1,200 shares in the last quarter. Raymond James Financial Inc. bought a new position in shares of Privia Health Group in the second quarter worth approximately $113,000. Covestor Ltd increased its position in shares of Privia Health Group by 39.8% in the third quarter. Covestor Ltd now owns 5,824 shares of the company’s stock worth $145,000 after purchasing an additional 1,657 shares during the last quarter. Finally, Acadian Asset Management LLC purchased a new stake in Privia Health Group in the first quarter valued at approximately $154,000. 94.48% of the stock is currently owned by hedge funds and other institutional investors.

Privia Health Group Price Performance

Shares of PRVA stock opened at $22.44 on Wednesday. The business has a 50-day moving average of $23.78 and a 200 day moving average of $23.21. Privia Health Group, Inc. has a 1-year low of $18.77 and a 1-year high of $26.51. The stock has a market capitalization of $2.76 billion, a PE ratio of 172.63, a P/E/G ratio of 1.64 and a beta of 0.83.

Privia Health Group (NASDAQ:PRVA) last released its quarterly earnings data on Thursday, November 6th. The company reported $0.29 earnings per share for the quarter, beating analysts’ consensus estimates of $0.06 by $0.23. Privia Health Group had a return on equity of 2.52% and a net margin of 0.89%.The firm had revenue of $580.42 million during the quarter, compared to analyst estimates of $494.98 million. During the same quarter in the prior year, the firm posted $0.20 earnings per share. The business’s quarterly revenue was up 32.5% compared to the same quarter last year. Analysts anticipate that Privia Health Group, Inc. will post 0.14 EPS for the current year.

Insiders Place Their Bets

In other news, Director Matthew Shawn Morris sold 13,647 shares of the stock in a transaction dated Friday, December 12th. The shares were sold at an average price of $25.01, for a total transaction of $341,311.47. Following the completion of the sale, the director directly owned 68,188 shares in the company, valued at approximately $1,705,381.88. This represents a 16.68% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO David Mountcastle sold 23,887 shares of the business’s stock in a transaction dated Friday, December 12th. The shares were sold at an average price of $25.03, for a total value of $597,891.61. Following the transaction, the chief financial officer owned 172,909 shares in the company, valued at approximately $4,327,912.27. This represents a 12.14% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 10.70% of the stock is owned by company insiders.

Analysts Set New Price Targets

A number of equities analysts have commented on PRVA shares. Canaccord Genuity Group boosted their price target on shares of Privia Health Group from $32.00 to $34.00 and gave the stock a “buy” rating in a research note on Wednesday, November 12th. Citizens Jmp upped their target price on shares of Privia Health Group from $30.00 to $31.00 and gave the stock a “market outperform” rating in a research report on Friday, November 7th. Barclays increased their price objective on Privia Health Group from $22.00 to $23.00 and gave the company an “equal weight” rating in a research report on Monday, November 10th. Stephens restated an “overweight” rating and issued a $32.00 target price on shares of Privia Health Group in a research report on Thursday, December 4th. Finally, Royal Bank Of Canada initiated coverage on shares of Privia Health Group in a research report on Friday, January 9th. They set an “outperform” rating and a $31.00 price target on the stock. Thirteen analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $30.50.

Privia Health Group Company Profile

Privia Health Group (NASDAQ: PRVA) is a physician enablement company that partners with independent physicians, medical groups and health systems to transform the delivery of patient care. Through a clinically integrated network and a proprietary technology platform, the company supports providers in managing population health, delivering coordinated care and optimizing financial performance under both fee-for-service and value-based reimbursement models.

Founded in 2016 and headquartered in McLean, Virginia, Privia Health has rapidly expanded its footprint to serve multiple metropolitan markets across the United States.